Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly traded biopharmaceutical company focused on the discovery, development, and commercialization of a cure for chronic hepatitis B virus (HBV) infection. The company is headquartered in Warminster, Pennsylvania, and it operates in the biotechnology and pharmaceutical industries.
History[edit]
Arbutus Biopharma was originally founded as Tekmira Pharmaceuticals Corporation in 2005. In 2015, the company rebranded itself as Arbutus Biopharma Corporation following the acquisition of OnCore Biopharma. The merger aimed to combine Tekmira's expertise in lipid nanoparticle (LNP) technology with OnCore's focus on HBV therapies.
Research and Development[edit]
Arbutus Biopharma's research and development efforts are primarily centered on finding a cure for chronic hepatitis B. The company's approach includes the development of RNA interference (RNAi) therapeutics, small molecule antivirals, and immune modulators.
RNA Interference (RNAi) Therapeutics[edit]
RNAi therapeutics are designed to silence specific genes associated with HBV replication. Arbutus has developed several RNAi candidates, including AB-729, which is currently in clinical trials.
Small Molecule Antivirals[edit]
Arbutus is also working on small molecule antivirals that target various stages of the HBV life cycle. These compounds aim to inhibit the replication of the virus and reduce the viral load in patients.
Immune Modulators[edit]
The company is exploring immune modulators to enhance the body's immune response against HBV. These therapies aim to boost the immune system's ability to recognize and eliminate HBV-infected cells.
Pipeline[edit]
Arbutus Biopharma has a robust pipeline of investigational drugs targeting HBV. Some of the key candidates include:
- AB-729: An RNAi therapeutic in clinical trials.
- AB-836: A capsid inhibitor designed to disrupt the HBV life cycle.
- AB-101: An immune modulator aimed at enhancing the immune response.
Collaborations and Partnerships[edit]
Arbutus Biopharma has established several collaborations and partnerships to advance its research and development efforts. Notable partners include Alnylam Pharmaceuticals, Genevant Sciences, and the Bill & Melinda Gates Foundation.
Financial Information[edit]
Arbutus Biopharma is listed on the NASDAQ stock exchange under the ticker symbol "ABUS." The company has secured funding through various rounds of financing, including public offerings and private investments.
See Also[edit]
References[edit]
External Links[edit]
| <img src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Searchtool.svg/40px-Searchtool.svg.png" alt="Stub icon" width="40" height="40" /> | This biopharmaceutical related article is a stub. You can help WikiMD by expanding it. |
